Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

101. Managing Menopause Chapter 8 Sexuality and Menopause

Managing Menopause Chapter 8 Sexuality and Menopause Managing Menopause Chapter 8 Sexuality and Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S59–S73 Managing Menopause Chapter 8 Sexuality and Menopause DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Figures Figure 8.1 Sexual problems and personal distress (...) by age In gynaecologic practice many peri- and postmenopausal women present to the physician with new complaints of changes in sexual desire or pain with intercourse that affects their relationships and quality of life. 1,2 Postmenopausal women are interested in sex for physical pleasure, intimacy, and expression of love, as well as to please their partner. 3 Maintenance of sexuality is important for the well-being of women as they navigate the emotional and physical challenges of menopause. 2,4

2014 Society of Obstetricians and Gynaecologists of Canada

102. Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer

Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S23–S30 Managing Menopause Chapter 3 Menopausal Hormone Therapy and Breast Cancer DOI: To view the full text, please login as a subscribed user or . Click to view the full text (...) on ScienceDirect. Breast cancer accounts for almost 25% of all cancers diagnosed in women (1.4 million cases worldwide survival differences can be attributed in part to early-detection programs and access to treatment, other factors in 2008), and it is clearly the greatest concern for women considering menopausal HT to ease their transition into menopause. The cumulative incidence of breast cancer among women in Europe and North America is about 2.7% by age 55, about 5.0% by age 65, and about 7.7% by age 75. 1

2014 Society of Obstetricians and Gynaecologists of Canada

103. Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms

Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Article Text Therapeutics Systematic review and meta-analysis Isoflavones hold limited promise

2014 Evidence-Based Medicine (Requires free registration)

104. Quantitative study?other: In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease

Quantitative study?other: In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease Article Text Nursing issues

2014 Evidence-Based Nursing

105. Laboratory Endocrine Testing Guidelines: Amenorrhea (without Hirsutism) and Menopause

Laboratory Endocrine Testing Guidelines: Amenorrhea (without Hirsutism) and Menopause LABORATORY ENDOCRINE TESTING: AMENHORRHEA (WITHOUT HIRSUTISM) AND MENOPAUSE Clinical Practice Guideline | January 2008 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Clinicians in Alberta optimize laboratory (...) tests for investigation of amenorrhea (without hirsutism) and suspected menopause TARGET POPULATION Women with primary amenorrhea Girls with the lack of breast development by age 14 years, or by the lack of menses by age 16 in the presence of normal secondary sexual development, or by the lack of menses by three years after the larche Women with secondary amenorrhea (more than six months without menses after prior establishment of menses) EXCLUSIONS Pregnant women RECOMMENDATIONS PRIMARY AMENORRHEA

2014 Toward Optimized Practice

106. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 21, No. 10, pp. 1063/1068 DOI: 10.1097/gme.0000000000000329 * 2014 by the European Menopause and Andropause Society, International Menopause Society, International Society for the Study of Women’s Sexual Health and The North American (...) Menopause Society SPECIAL FEATURE Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women_s Sexual Health and The North American Menopause Society David J. Portman, MD, 1 Margery L.S. Gass, MD, NCMP, 2 on behalf of the Vulvovaginal Atrophy Terminology Consensus Conference Panel Abstract Background: In 2012, the Board of Directors of the International Society for the Study of Women’s Sexual Health(ISSWSH

2014 The North American Menopause Society

107. Menopause Chapter 5: Clinical Evaluation and Counseling

Menopause Chapter 5: Clinical Evaluation and Counseling Chapter 5: Clinical Evaluation and Counseling | | | | Chapter 5: Clinical Evaluation and Counseling > > > HISTORY AND PHYSICAL EXAM Key Points The health evaluation at the time of the menopause transition should be tailored to the individual woman based on her medical, social, and family history, as well as on her symptoms and quality-of-life goals. Sexual and psychological histories are an important part of the assessment of women during (...) the menopause transition. The evidence supporting various aspects of the physical exam, including the clinical breast exam and bimanual pelvic exam, is limited and contradictory. Recommendations for Clinical Care A thorough history and focused physical exam can guide clinicians and their patients in managing the symptoms of the menopause transition and providing guidance to support enhanced health for women as they age. (Level II) The evaluation and counseling of a midlife woman should be individualized

2014 The North American Menopause Society

108. Menopause Chapter 4: Disease Risk

Menopause Chapter 4: Disease Risk Chapter 4: Disease Risk | | | | Chapter 4: Disease Risk > > > CARDIOVASCULAR HEALTH Key Points Cardiovascular disease (CVD) is the leading cause of death in women worldwide. Major risk factors for CVD in women include age, hypertension, dyslipidemia, diabetes mellitus (DM), family history of premature CVD, smoking, sedentary lifestyle, and poor diet. Novel risk factors for CVD include a history of a pregnancy complicated by preeclampsia, gestational diabetes (...) , or hypertension. Hormonal changes associated with menopause can result in an accelerated increase in low-density lipoprotein cholesterol (LDL-C) in the year following menopause. Recommendations for Clinical Care All women should be encouraged to reduce their risk for CVD, including heart attack and stroke, by engaging in regular exercise, consuming a healthy diet, achieving a normal body weight, and not smoking. Healthcare providers should evaluate all women for CVD risk using the American College

2014 The North American Menopause Society

109. Chapter 1: Menopause

Chapter 1: Menopause Chapter 1: Menopause | | | | Chapter 1: Menopause > > > OVERVIEW OF MENOPAUSE Key Points Menopause is a normal physiologic event, defined as the final menstrual period (FMP) and reflecting loss of ovarian follicular function. Spontaneous or natural menopause is recognized retrospectively after 12 months of amenorrhea. It occurs at an average age of 52 years, but the age of natural menopause can vary widely from 40 to 58 years. Induced menopause refers to the cessation (...) of menstruation that occurs after either bilateral oophorectomy or iatrogenic ablation of ovarian function (eg, by chemotherapy or pelvic radiation). The Stages of Reproductive Aging Workshop (STRAW) established a nomenclature and a staging system for the female reproductive aging continuum in 2001, which was revised in 2011 with the STRAW + 10 staging system. According to STRAW + 10, the term menopause transition refers to the span of time when menstrual cycle and endocrine changes occur, beginning

2014 The North American Menopause Society

110. Menopause Chapter 3: Clinical Issues

Menopause Chapter 3: Clinical Issues Chapter 3: Clinical Issues | | | | Chapter 3: Clinical Issues > > > DECLINE IN FERTILITY Key Points Fertility declines with increasing age, notably after age 35 years, or approximately 15 years before menopause. Age-related declines in fertility have been confirmed in epidemiologic studies as well as by the observation of declining pregnancy rates with advancing age in cycles of donor insemination and in vitro fertilization (IVF). Advanced maternal age (≥35 (...) . (Level II) In older women undergoing oocyte-donation IVF, single-embryo transfer should be strongly considered because of the risks associated with multiple births. (Level II) Women of advancing age considering donor-oocyte IVF should be counseled about parenting issues and health concerns specific to their age and the age and health of their partner. (Level II) UTERINE BLEEDING Key Points Approximately 90% of women experience 4 to 8 years of menstrual cycle changes before natural menopause, which

2014 The North American Menopause Society

111. Menopause Chapter 2: Midlife Body Changes

Menopause Chapter 2: Midlife Body Changes Chapter 2: Midlife Body Changes | | | | Chapter 2: Midlife Body Changes > > > VULVOVAGINAL CHANGES Key Points Postmenopausal estrogen loss and aging accompanied by physiologic, vascular, neurologic, and histologic changes may result in vulvovaginal symptoms, including irritation, burning, itching, vaginal discharge, postcoital bleeding, and dyspareunia. Genitourinary syndrome of menopause (GSM), a syndrome that encompasses symptomatic vulvovaginal (...) atrophy (VVA), may have a significant impact on the quality of life of midlife women, with effects on sexual function and interpersonal relationships. Women of any age with low estrogen levels, including women with primary ovarian insufficiency, premature menopause, hypothalamic amenorrhea, or hyperprolactinemia; during lactation; or after treatment with gonadotropin-releasing hormone (GnRH) agonists/antagonists or aromatase inhibitors, may experience symptoms of GSM/VVA. The presentation, diagnosis

2014 The North American Menopause Society

112. Menopause Chapter 8: Prescription Therapies

Menopause Chapter 8: Prescription Therapies Chapter 8: Prescription Therapies | | | | Chapter 8: Prescription Therapies > > > CONTRACEPTIVES Key Points Despite a decline in fertility, women of older reproductive age who do not wish to conceive should use effective contraception until 1 year after the final menstrual period. Long-acting reversible contraceptive methods, which include the copper intrauterine device (IUD), the two levonorgestrel intrauterine systems, and the etonogestrel subdermal (...) with a uterus. Systemic HT and low-dose vaginal ET are very effective treatments for moderate to severe symptoms of vulvar and vaginal atrophy (vaginal dryness, dyspareunia, and atrophic vaginitis). The estrogen agonist/antagonist ospemifene is a new oral agent approved for this indication. Recommendations for Clinical Care The lowest dose of HT should be used for the shortest duration needed to manage menopausal symptoms. Individualization is important in the decision to use HT and should incorporate

2014 The North American Menopause Society

113. Menopause Chapter 7: Nonprescription Options

Menopause Chapter 7: Nonprescription Options Chapter 7: Nonprescription Options | | | | Chapter 7: Nonprescription Options > > > GOVERNMENT REGULATIONS FOR DIETARY SUPPLEMENTS Key Points Regulation of prescription drugs as well as over-the-counter (OTC) drugs by FDA is explicit and defined by federal statutes contained in the 1938 Federal Food, Drug, and Cosmetic Act (FDCA). This Act is continually being amended and updated. New prescription drug marketing approval and postmarketing safety (...) trials of calcium in combination with vitamin D demonstrate a role in fracture prevention. The main dietary sources of calcium are dairy products (including milk, cheese, and yogurt), which provide an average of 70% of the total calcium intake in midlife and older women. Calcium requirements for skeletal maintenance in women fluctuate throughout life but increase after menopause due to increased bone resorption and decreased intestinal calcium absorption, both of which are associated with decreased

2014 The North American Menopause Society

114. Menopause Chapter 6: Complementary and Alternative Medicine

Menopause Chapter 6: Complementary and Alternative Medicine Chapter 6: Complementary and Alternative Medicine | | | | Chapter 6: Complementary and Alternative Medicine > > > INTEGRATIVE MEDICINE Key Points A National Institutes of Health survey found that 36% of Americans use some form of complementary and alternative medicine (CAM). When megavitamin use and prayer for health reasons are included in the definition of CAM, the percentage rises to 62%. Increased dietary soy (legumes, soy, tofu (...) ), isoflavone products, and other forms of phytoestrogens reduce menopause symptoms, although clinical trials demonstrate benefit generally similar to that of placebo. Acupuncture reduces hot flashes and improves sleep patterns in postmenopausal women, although clinical trials demonstrate benefit generally similar to that of sham acupuncture. Regular consumption of soy isoflavones in the diet may offer breast cancer protection if exposure occurs during breast development. Soy isoflavones also may inhibit

2014 The North American Menopause Society

115. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence

Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Conjugated equine estrogens plus medroxyprogesterone (MPA) did not increase the risk of developing atrial fibrillation, increased the risk of invasive breast cancer, and increased the incidence of deaths attributed to lung cancer compared to placebo in the Women's Health Initiative study

2014 Health Technology Assessment (HTA) Database.

116. Oral progesterone for the treatment of menopausal symptoms: clinical evidence

Oral progesterone for the treatment of menopausal symptoms: clinical evidence Oral progesterone for the treatment of menopausal symptoms: clinical evidence Oral progesterone for the treatment of menopausal symptoms: clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oral progesterone for the treatment (...) of menopausal symptoms: clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review, 23 publications from randomized controlled trials, and two non-randomized studies were identified regarding the clinical efficacy of micronized progesterone or medroxyprogesterone, or the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone, for the management of menopausal symptoms. Final publication

2014 Health Technology Assessment (HTA) Database.

117. Randomised controlled trial: Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase

Randomised controlled trial: Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Article Text Prevention Randomised controlled trial Menopausal hormone

2014 Evidence-Based Medicine (Requires free registration)

118. Bone Densitometry testing for menopausal women aged 50

Bone Densitometry testing for menopausal women aged 50 Ap ene Spons Date o Context at www 1. An appl women The app spine bo stage, id individu would b 2. After co effectiv 50 year ? ? 3. MSAC and lum year in risk and pplicatio ergy X-ra sor/Applica of MSAC c t for decisio w.msac.gov. Purpose o lication req in their 50 t plication pro one densito dentifying i uals with a n be given app MSAC’s a onsidering t veness, MSA rs. This was There was n assessment Currently M Summary noted that t mbar (...) , this target population would not have a combination of risk factors (eg being female and peri-menopausal) that would sufficiently differentiate the requested testing arrangements from a primary health screening service given that they are otherwise healthy. In this regard, MSAC noted that Section 19 (5) of the Health Insurance Act 1973 generally prevents payment of Medicare benefits for screening services stating: "Unless the Minister otherwise directs, a Medicare benefit is not payable in respect

2014 Medical Services Advisory Committee

119. Salivary hormone testing for menopausal women

Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Salivary hormone testing for menopausal women. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors' conclusions Salivary hormone testing (SHT) is used to measure levels (...) of hormones, including estrogens, progestogens, androgens, and cortisol. Compared with hormone testing in blood, salivary hormone testing is noninvasive and saliva can be collected by patients at home. Salivary hormone testing is often recommended for women who receive hormone replacement therapy, especially women who receive compounded hormone preparations. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Female; Hormones; Humans; Menopause

2013 Health Technology Assessment (HTA) Database.

120. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. (PubMed)

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.A total of 27,347 postmenopausal women

Full Text available with Trip Pro

2013 JAMA